Bouare N, Delwaide J. Interleukin-mediated therapies in liver diseases and comorbidity effects. World J Hepatol 2024; 16(7): 980-989 [PMID: 39086534 DOI: 10.4254/wjh.v16.i7.980]
Corresponding Author of This Article
Nouhoum Bouare, DSc, PhD, Research Scientist, Senior Lecturer, Senior Researcher, Department of Quality, Hygien, Biosafety/Biosecurity and Pharmacovigilence, National Institute of Public Health, Hippodrome Rue Hamilcar Cabral Bamako, Bamako 1771, Mali. nouhoumsamakoro@yahoo.fr
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Jul 27, 2024; 16(7): 980-989 Published online Jul 27, 2024. doi: 10.4254/wjh.v16.i7.980
Interleukin-mediated therapies in liver diseases and comorbidity effects
Nouhoum Bouare, Jean Delwaide
Nouhoum Bouare, Department of Quality, Hygien, Biosafety/Biosecurity and Pharmacovigilence, National Institute of Public Health, Bamako 1771, Mali
Jean Delwaide, Department of Gastroenterology and Hepatology, CHULiege, Liege 4000, Belgium
Author contributions: Bouare N designed, drafting and contributed to reviewing the manuscript; Delwaide J contributed by drafting and reviewing the manuscript; All authors reviewed, read and approved the final version of the manuscript.
Conflict-of-interest statement: Any conflict of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4. 0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Nouhoum Bouare, DSc, PhD, Research Scientist, Senior Lecturer, Senior Researcher, Department of Quality, Hygien, Biosafety/Biosecurity and Pharmacovigilence, National Institute of Public Health, Hippodrome Rue Hamilcar Cabral Bamako, Bamako 1771, Mali. nouhoumsamakoro@yahoo.fr
Received: February 28, 2024 Revised: May 13, 2024 Accepted: May 17, 2024 Published online: July 27, 2024 Processing time: 148 Days and 16.6 Hours
Core Tip
Core Tip: Interleukin-mediated monotherapy and synergistic treatment experiments are certainly interesting for scientific insights. Overcoming clinical trials challenges a fortiori linked to the liver-comorbid condition, new drugs development models are being experienced, such as dissecting the molecular subphenotypes which favour disease progression, promoting the precision medicine through multiomics analysis, and promoting the safe, long-lasting and effective antiviral formulations. However, a judicious exploitation of newly available data, and applying related-useful findings pertaining to comorbidity pathway and a multidisciplinary approach, should efficiently address liver diseases management in a short-term a fortiori to avoid long-term complications.
